

A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF

Submission date 17/07/2017	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/10/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 30/06/2025	Condition category Respiratory	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Cystic Fibrosis (CF) is a genetic condition that causes the lungs and digestive system to be clogged with mucus. It affects 10000 people in the UK. The lungs of people with CF (PWCF) are prone to infections and require daily medication to stay healthy. Average adherence to medication has been shown to be only 36%. Poor adherence is associated with poor clinical outcomes including distressing unscheduled hospitalisations. Researchers have designed an intervention that will feedback adherence data to PWCF using chipped nebulisers displaying real-time treatment use on smartphones and the website (CFHealthhub). Feedback is a powerful support to habit formation and the use of the CFHealthHub and a behaviour change manual to support PWCF in building successful treatment habits. The aim of this study is to assess whether the use of the CFHealthHub intervention, which includes the toolkit and website, reduces the amount of unscheduled emergency care PWCF require compared to those receiving standard care.

Who can participate?

Aged 16 years and older who are diagnosed with CF and are willing to take inhaled mucolytics or antibiotics via a chipped nebuliser.

What does the study involve?

Participants are randomly allocated to groups. Those in the first group receive their usual care. Those in the second group receive the CFHealthHub and behaviour change manual to support them in building successful treatment habits. Participants are followed for 12 months and data is collected about their exacerbations and their adherence in treatment.

What are the possible benefits and risks of participating?

Participants may benefit from being able to access their CFHealthhub group and a record of

their nebuliser use. Participants may find feedback treatment useful in making treatments a regular and routine part of life. The main risk/disadvantage to participation is giving up time to attend the appointments. Appointments will vary from 10 minutes (over the phone) to up to one hour when more data is collected.

Where is the study run from?

This study is being run by the University of Sheffield (UK) and takes place in hospitals in the UK.

When is the study starting and how long is it expected to run for?

January 2019 to December 2019

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Mrs Chin Maguire

c.maguire@sheffield.ac.uk

Contact information

Type(s)

Public

Contact name

Mrs Chin Maguire

ORCID ID

<https://orcid.org/0000-0002-9397-7608>

Contact details

Clinical Trials Research Unit

University of Sheffield

Scharr

30 Regent Street

Sheffield

United Kingdom

S1 4DA

+44 0114 222 0717

c.maguire@sheffield.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 33345

Study information

Scientific Title

Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis: A randomised controlled trial and parallel process evaluation

Acronym

ACTiF

Study objectives

The aim of this study is to assess whether use of the CFHealthHub intervention, which includes the toolkit and website, reduces the amount of unscheduled emergency care PWCF require compared to those receiving standard care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

REC London - Brent Research Ethics Committee, 02/03/2017, ref: 17/LO/0035

Study design

Randomized; Interventional; Design type: Prevention, Process of Care, Education or Self-Management, Device, Psychological & Behavioural, Complex Intervention

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Specialty: Respiratory disorders, Primary sub-specialty: Respiratory disorders; UKCRC code/ Disease: Congenital Disorders/ Congenital malformations of the respiratory system

Interventions

The study is a mixed method study comprising a Quantitative component (parallel group, open labelled, external RCT) and a Qualitative component (audio recordings of consultations and interviews). Both quantitative and qualitative data will contribute to the process evaluation. The main aims of the study are to determine whether the intervention offers any benefit over usual care in adult patients with CF.

Once consent and eligibility for the study have been determined, study participants are randomised to either the intervention arm (CFHealthHub) or control arm (usual care) via the Sheffield Clinical Trials Research Unit web randomisation system. Participants in both groups contribute adherence data to CFHealthHub but only those randomised to the intervention arm have access to interact with CFHealthHub to manage their treatment habits. This is done via a combination of face to face (or telephone/email contact sessions) with the trial interventionists and using CFHealthHub as a tool independently between sessions.

The mean number of Pulmonary Exacerbations (PE) per patient in the 12-month post-consent follow-up as determined by the Fuch's criteria is assessed. Each participant is followed up for 12 months. Research data is collected at a number of time points including baseline, standard clinic visits, during intervention sessions and at 12 months. Exacerbation data is collected at each point of an exacerbation. Data relating to intervention delivery are also collated during the course of the trial. Qualitative data are collected during interviews with interventionists and intervention arm participants to determine the acceptability of CFHealthHub. Audio recordings from each intervention delivery session are used to assess the fidelity of the intervention.

Beyond the 12 month visit, participants continue to contribute adherence data to CFHealthHub till 30/6/2019. During this period, those in the intervention arm can continue to receive support from the interventionists or use CFHealthHub independently.

Intervention Type

Other

Primary outcome(s)

Number of exacerbations are measured based on the modified Fuch's criteria and determined by a combination of hospital and participant input at baseline to June 2019.

Key secondary outcome(s)

1. Patient knowledge, skills, and confidence for self-management is measured using Patient Activation Measure (PAM-13) at baseline and 12 months
2. Life chaos is measured using Assessment of routine at baseline and 12 months
3. Generic health status is measured using the EuroQuol (EQ5d-5L) at baseline, 12 months and around points of exacerbations
4. Habit based behavioural patterns are measured using Self-Report Behavioural Automaticity Index (SRBAI) at baseline and 12 months
5. Disease specific quality of life is measured using Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline and 12 months
6. Depression severity is measured using the Patient Health Questionnaire depression scale (PHQ-8) at baseline and 12 months
7. Medication adherence is measured using MAD (Medication Adherence Data-3 items) at baseline and 12 months
8. Anxiety severity is measured using the General Anxiety Disorder 7-item anxiety scale (GAD-7) at baseline and 12 months
9. Beliefs about medication (specifically nebuliser use) is measured using The Capability Opportunity Motivation Behaviour Beliefs Questionnaire (COM-BMQ) at baseline and 12 months
10. Behaviour is measured using Behavioural question and questionnaire at baseline and 12 months
11. Clinical measures is measured using Medical adherence questions, BMI FEV1/FVC at baseline to end of study
12. Resource use is measured using questionnaire at 12 month visit

Completion date

30/12/2019

Eligibility

Key inclusion criteria

1. Diagnosed with CF and with data within the CF registry
2. Aged 16 years and above
3. Willing and able to take inhaled mucolytics or antibiotics via a chipped nebuliser (e.g. eTrack)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

16 years

Sex

All

Total final enrolment

608

Key exclusion criteria

1. Post-lung transplant
2. People on the active lung transplant list
3. Patients receiving palliative care, with palliative intent, for whom trial participation could be a burden
4. Participants who lack capacity to give informed consent
5. Participants using dry powder devices to take antibiotics or mucolytics

Date of first enrolment

02/10/2017

Date of final enrolment

30/05/2018

Locations**Countries of recruitment**

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre
Frimley Park Hospital
Portsmouth Road
Frimley
Camberley
United Kingdom
GU16 7UJ

Study participating centre
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
United Kingdom
NE1 4LP

Study participating centre
Royal Stoke University Hospital
Newcastle Road
Staffordshire
Stoke-on-Trent
United Kingdom
ST4 6QG

Study participating centre
Papworth Hospital
Papworth Everard
Cambridge
United Kingdom
CB23 3RE

Study participating centre
John Radcliffe Hospital
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU

Study participating centre

St Bartholomew's Hospital

W Smithfield
London
United Kingdom
EC1A 7BE

Study participating centre

Bristol Royal Infirmary

Upper Maudlin Street
Bristol
United Kingdom
BS2 8HW

Study participating centre

King's College Hospital

Denmark Hill
Brixton
London
United Kingdom
SE5 9RS

Study participating centre

Belfast City Hospital

Lisburn Road
Belfast
United Kingdom
BT9 7AB

Study participating centre

Royal Brompton Hospital

Sydney Street
Chelsea
London
United Kingdom
SW3 6NP

Study participating centre

Derriford Hospital

Derriford Road
Crownhill
Plymouth

United Kingdom
PL6 8DH

Study participating centre

Glenfield Hospital

Groby Road
Leicester
United Kingdom
LE3 9QP

Study participating centre

Cardiff and Vale University Health Board

Cardiff
United Kingdom
CF14 4XW

Study participating centre

Western General Hospital

Crewe Road S
Edinburgh
United Kingdom
EH4 2XU

Study participating centre

Birmingham Heartlands Hospital

Bordesley Green E
Birmingham
United Kingdom
B9 5SS

Study participating centre

Norfolk and Norwich University Hospital

Colney Lane
Norwich
United Kingdom
NR4 7UY

Study participating centre

Royal Cornwall Hospital

Treliske

Truro

United Kingdom

TR1 3LQ

Study participating centre**York Hospital**

Wigginton Road

York

United Kingdom

YO31 8HE

Study participating centre**Hull Royal Infirmary**

Anlaby Road

Hull

United Kingdom

HU3 2JZ

Study participating centre**Royal Devon and Exeter Hospital**

Barrack Road

Exeter

United Kingdom

EX2 5DW

Sponsor information

Organisation

Sheffield Teaching Hospitals NSH Foundation Trust

ROR

<https://ror.org/018hjpz25>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Amanda Loban, Data Manager (a.loban@sheffield.ac.uk). A formal request will need to be submitted and reviewed by the Study Trial Management group. The group will consider, at the time of the request, the type of data, any restrictions on this and the mechanism by which this will be shared on a case-by-case basis.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		23/09/2021	08/11/2023	Yes	No
Results article		01/10/2021	08/11/2023	Yes	No
Basic results		30/09/2020	01/10/2020	No	No
HRA research summary			28/06/2023	No	No
Other publications	fidelity assessment	21/03/2024	30/06/2025	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes